Skip to content

czifan/HER2.pytorch

Folders and files

NameName
Last commit message
Last commit date

Latest commit

 

History

3 Commits
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Repository files navigation

A deep learning model for predicting benefit from anti-HER2 targeted therapy in metastatic gastric cancer using multifocal and time-series CT images

Introduction

This repository is the official PyTorch implementation of A deep learning model for predicting benefit from anti-HER2 targeted therapy in metastatic gastric cancer using multifocal and time-series CT images.

Objectives

Due to the unique spatiotemporal heterogeneity of metastatic gastric cancer (mGC), the existing size-based criteria are difficult to predict the benefit of anti-HER2 targeted therapy. This study aimed to propose a novel criterion based on deep learning that integrated such heterogeneity to enhance the accuracy of predicting prognosis and response in patients with mGC receiving anti-HER2 targeted therapy.

Methods

This multi-central study enrolled from one center 137 patients for retrospectively internal training/validation and 33 patients for prospective evaluation and recruited 37 patients from another three centers for external validation. All patients received anti-HER2-targeted therapy, underwent pre- and post-treatment CT scans (baseline and at least one follow-up), and only the patients from the first center were collected with tumor markers. The proposed deep learning model evaluated the lesions in time-series CTs or tumor markers to predict risk probabilities. Furthermore, we built a Nomogram to aggregate the risk probabilities and clinical information to compute the treatment risk.

Results

Experimental results showed that our model achieved AUC scores of 0.894 (0.768-1.019) and 0.809 (0.561-1.056) in the internal validation and prospective cohort. The AUC score in the external validation cohort was 0.771 (0.510-1.031) using only time-series CTs. The results also showed that patients with low-risk scores derived survival benefits from anti-HER2 targeted therapy significantly more than those with high-risk scores (all P<0.05).

Conclusions

The proposed method has the potential to effectively read the probability of the future benefit in patients with HER-2-positive mGC and reveal clinical patterns across lesions and time series.

image

Requirements

  • Pytorch>=1.1.0
  • CPU or GPU
  • Other packages can be installed with the following command:
pip install requirements.txt

Quick start

Runing the following command to train and evaluate the model:

python train.sh

Results

We have constructed several models:

Models CT(BS) CT(1F) CT(2F) Tumor markers RECIST Clinical info. Descriptions
RECIST v1.1 Based on RECIST v1.1,treatment response is defined as PR, SD and PD
TB-Δ change of percentage in tumor size
LDLM-BS LDLM based on baseline CT scans
LDLM-1F LDLM based on baseline and the first one follow-up CT scans
LDLM-2F LDLM based on baseline and the first two follow-up CT scans
TDLM Based on serial tumor markers
Nomo-wot Nomogram integrated by LDLM, RECIST, and clinical information
Nomo-all Nomogram integrated by LDLM, TDLM, RECIST, and clinical information

Performance comparisions of differnet models on the training cohort (n=91):

Models C-index (95% CI) HR (95% CI) HR (P value) AUC (95% CI)
RECIST v1.1 0.648 (0.577-0.719) 1.858 (1.363-2.534) <0.0001 0.753 (0.636-0.869)
TB-Δ 0.613 (0.527-0.698) 1.006 (1.000-1.013) 0.0447 0.675 (0.545-0.804)
LDLM-BS 0.661 (0.594-0.728) 4.715 (1.939-11.466) 0.0006 0.744 (0.620-0.868)
LDLM-1F 0.721 (0.655-0.787) 5.573 (2.834-10.958) <0.0001 0.771 (0.661-0.880)
LDLM-2F 0.775 (0.717-0.833) 25.409 (9.676-66.725) <0.0001 0.879 (0.792-0.966)
TDLM 0.717 (0.641-0.792) 9.230 (3.825-22.274) <0.0001 0.780 (0.666-0.894)
Nomo-wot 0.795 (0.740-0.851) 73.613 (24.399-222.092) <0.0001 0.903 (0.819-0.987)
Nomo-all 0.807 (0.748-0.866) 115.751 (34.611-387.108) <0.0001 0.891 (0.808-0.975)

Performance comparisions of differnet models on the internal validation cohort (n=46):

Models C-index (95% CI) HR (95% CI) HR (P value) AUC (95% CI)
RECIST v1.1 0.652 (0.525-0.780) 1.583 (1.100-2.277) 0.0133 0.759 (0.580-0.938)
TB-Δ 0.594 (0.471-0.718) 1.011 (1.000-1.022) 0.0456 0.651 (0.437-0.866)
LDLM-BS 0.632 (0.501-0.762) 3.225 (0.993-10.473) 0.0513 0.701 (0.530-0.872)
LDLM-1F 0.721 (0.613-0.828) 8.958 (2.525-31.780) 0.0007 0.838 (0.702-0.975)
LDLM-2F 0.725 (0.614-0.836) 25.111 (4.535-139.034) 0.0002 0.844 (0.702-0.986)
TDLM 0.718 (0.601-0.834) 15.172 (2.527-91.080) 0.0029 0.867 (0.756-0.978)
Nomo-wot 0.736 (0.602-0.869) 31.678 (6.390-157.050) <0.0001 0.836 (0.661-1.011)
Nomo-all 0.752 (0.634-0.870) 23.911 (5.229-109.337) <0.0001 0.894 (0.768-1.019)

Performance comparisions of differnet models on the external validation cohort (n=37):

Models C-index (95% CI) HR (95% CI) HR (P value) AUC (95% CI)
RECIST v1.1 0.627 (0.510-0.745) 2.125 (1.147-3.937) 0.0166 0.653 (0.422-0.883)
TB-Δ 0.527 (0.376-0.677) 1.001 (0.993-1.010) 0.7578 0.516 (0.249-0.782)
DL-BS 0.619 (0.487-0.751) 5.232 (0.823-33.237) 0.0794 0.583 (0.339-0.827)
DL-1F 0.632 (0.467-0.797) 5.132 (0.361-72.99) 0.2272 0.696 (0.439-0.953)
DL-2F 0.669 (0.503-0.836) 10.553 (0.713-156.072) 0.0865 0.683 (0.400-0.967)
Nomo-wot 0.709 (0.562-0.855) 13.837 (1.846-103.746) 0.0106 0.771 (0.510-1.031)

Performance comparisions of differnet models on the prospective cohort (n=33):

Models C-index (95% CI) HR (95% CI) HR (P value) AUC (95% CI)
RECIST v1.1 0.644 (0.501-0.786) 1.343 (0.880-2.048) 0.1710 0.770 (0.579-0.961)
TB-Δ 0.630 (0.473-0.786) 1.007 (1.001-1.012) 0.0226 0.738 (0.486-0.989)
LDLM-BS 0.524 (0.358-0.690) 1.499 (0.229-9.795) 0.6724 0.472 (0.218-0.725)
LDLM-1F 0.630 (0.463-0.796) 2.983 (0.598-14.875) 0.1824 0.536 (0.241-0.832)
LDLM-2F 0.726 (0.580-0.873) 24.972 (2.608-239.116) 0.0052 0.690 (0.419-0.962)
TDLM 0.595 (0.444-0.747) 2.666 (0.354-20.068) 0.3411 0.678 (0.440-0.915)
Nomo-wot 0.758 (0.608-0.908) 15.718 (2.481-99.578) 0.0034 0.803 (0.554-1.051)
Nomo-all 0.741 (0.594-0.888) 8.809 (1.701-45.624) 0.0095 0.809 (0.561-1.056)

Citation

About

No description, website, or topics provided.

Resources

Stars

Watchers

Forks

Releases

No releases published

Packages

No packages published